0001493152-21-015911.txt : 20210701
0001493152-21-015911.hdr.sgml : 20210701
20210701215631
ACCESSION NUMBER: 0001493152-21-015911
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210330
FILED AS OF DATE: 20210701
DATE AS OF CHANGE: 20210701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boehm Marcus
CENTRAL INDEX KEY: 0001850698
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35817
FILM NUMBER: 211067879
MAIL ADDRESS:
STREET 1: C/O VYANT BIO, INC.
STREET 2: 201 ROUTE 17 NORTH, 2ND FLOOR
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vyant Bio, Inc.
CENTRAL INDEX KEY: 0001349929
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 043462475
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2370 STATE ROUTE 70 WEST
STREET 2: SUITE 310
CITY: CHERRY HILL,
STATE: NJ
ZIP: 08002
BUSINESS PHONE: 201.528.9200
MAIL ADDRESS:
STREET 1: 2370 STATE ROUTE 70 WEST
STREET 2: SUITE 310
CITY: CHERRY HILL,
STATE: NJ
ZIP: 08002
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS, INC
DATE OF NAME CHANGE: 20111216
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS INC
DATE OF NAME CHANGE: 20060117
4/A
1
ownership.xml
X0306
4/A
2021-03-30
2021-04-01
0
0001349929
Vyant Bio, Inc.
VYNT
0001850698
Boehm Marcus
C/O VYANT BIO, INC.
2370 STATE ROUTE 70, SUITE 310
CHERRY HILL,
NJ
08002
1
0
0
0
Common Stock, $0.0001 par value
2021-03-30
4
J
0
93786
A
93786
D
Common Stock, $0.0001 par value
2021-05-05
5
G
0
E
78263
0
D
15253
D
Common Stock, $0.0001 par value
2021-05-05
5
G
0
E
78263
0
A
78263
I
By Trust
Common Stock, $0.0001 par value
2021-05-10
5
G
0
E
15523
0
D
0
D
Common Stock, $0.0001 par value
2021-05-10
5
G
0
E
15523
0
A
93786
I
By Trust
Common Stock, $0.0001 par value
2021-05-28
4
P
0
5000
3.68
A
98786
I
By Trust
Common Stock, $0.0001 par value
2021-06-30
4
P
0
5000
3.7649
A
103786
I
By Trust
Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person under the Boehm Family Trust, Marcus & Kimberley Boehm Trustees on May 24, 2021.
Shares were previously reported as being directly held by reporting person.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.8099 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
This amended Form 4 is being filed to correct (i) the number of shares issued pursuant to the merger on March 30, 2021, (ii) reporting person's indirect purchase of shares (via a trust) on May 28, 2021 and (iii) the disclosure of shares previously owned directly that were transferred to a trust reported on the Form 4 filed July 1, 2021.
/s/ Andrew LaFrence, attorney-in-fact
2021-07-01